A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6371-6377

  Da Silva, Gilberto Marcelo Sperandio ^a   Mediano, Mauro Felippe Felix ^a   Do Brasil, Pedro Emmanuel Alvarenga Americano ^a   Da Costa Chambela, Mayara ^a   Silva, Da Joyce Almeida ^a   De Sousa, Andrea Silvestre ^a   Xavier, Sergio Salles ^a   Da Costa, Andrea Rodrigues ^a   Saraiva, Roberto Magalhães ^a   Hasslocher Moreno, Alejandro Marcel ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; ANTITRYPANOSOMAL AGENT; BIOLOGICAL MARKER; NITROIMIDAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ARTICLE; AUTONOMIC NEUROPATHY; BLACK PERSON; CAUCASIAN; CENTRAL NERVOUS SYSTEM DISEASE; CHAGAS DISEASE; DRUG ERUPTION; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOCYTE DISORDER; MAJOR CLINICAL STUDY; MALE; MULATTO; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PREDICTION; PRIMARY SCHOOL; PRURITUS; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; VISUAL DISORDER; ANCESTRY GROUP; DRUG EFFECTS; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PARASITOLOGY; STATISTICAL MODEL; TRYPANOSOMA CRUZI; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOMARKERS; CHAGAS DISEASE; CONTINENTAL POPULATION GROUPS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EDUCATIONAL STATUS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; NITROIMIDAZOLES; SEX FACTORS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; YOUNG ADULT;

EID: 84908565393     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02842-14     Document Type: Article

References (50)

1. Chagas C. 1909. Nova tripanozomiaze humana. Mem. Inst. Oswaldo Cruz 1:159-218. http://dx.doi.org/10.1590/S0074-02761909000200008
2. Lannes-Vieira J, de Araujo-Jorge TC, Soeiro Mde N, Gadelha P, Correa-Oliveira R. 2010. The centennial of the discovery of Chagas disease: facing the current challenges. PLoS Negl. Trop. Dis. 4:e645. http://dx.doi.org/10 .1371/journal.pntd.0000645
3. Moncayo A, Silveira AC. 2009. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem. Inst. Oswaldo Cruz 104(Suppl 1):S17-S30. http://dx.doi.org/10.1590/S0074-02762009000900005
4. Perez-Molina JA, Norman F, Lopez-Velez R. 2012. Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment. Curr. Infect. Dis. Rep. 14:263-274. http://dx.doi.org/10.1007/s11908-012-0259-3
5. Aagaard-Hansen J, Nombela N, Alvar J. 2010. Population movement: a key factor in the epidemiology of neglected tropical diseases. Trop. Med. Int. Health 15:1281-1288. http://dx.doi.org/10.1111/j.1365-3156.2010 .02629.x
6. Gascon J, Bern C, Pinazo MJ. 2010. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 115:22-27. http://dx.doi.org/10.1016/j.actatropica.2009.07.019
7. Schmunis GA, Yadon ZE. 2010. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. 115:14-21. http://dx.doi.org/10.1016/j.actatropica.2009.11.003
8. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, Roddy P, Parreno F, Albajar Vinas P, Palma PP. 2009. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl. Trop. Dis. 3:e488. http://dx.doi.org/10.1371/journal.pntd.0000488
9. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. 2002. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst.Rev. 5:CD003463
10. Rassi A, Jr, Rassi A, Marcondes de Rezende J. 2012. American trypanosomiasis (Chagas disease). Infect. Dis. Clin. North Am. 26:275-291. http://dx.doi.org/10.1016/j.idc.2012.03.002
11. Rassi A, Jr, Rassi A, Marin-Neto JA. 2010. Chagas disease. Lancet 375: 1388-1402. http://dx.doi.org/10.1016/S0140-6736(10)60061-X
12. Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R. 2009. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J. Antimicrob. Chemother. 64:1139-1147. http://dx.doi.org/10.1093/jac/dkp357
13. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A. 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 144:724-734. http://dx.doi.org/10.7326/0003-4819-144-10-200605160-00006
14. Cancado JR. 2002. Long-term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo 44:29-37. http://dx.doi.org/10.1590/S0036-46652002000100006
15. Bern C. 2011. Antitrypanosomal therapy for chronic Chagas' disease. N. Engl. J. Med. 364:2527-2534. http://dx.doi.org/10.1056/NEJMct1014204
16. Ministerio da Saude Secretaria de Vigilancia em Saúde. 2005. Brazilian consensus on Chagas disease. Rev. Soc. Bras. Med. Trop. 38(Suppl. 3):7-29. (In Portugese.)
17. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. 2007. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298:2171-2181. http://dx.doi.org/10.1001/jama.298.18.2171
18. WHO. 2002. Control of Chagas disease: report of aWHOexpert committee. World Health Organization. Technical report series, no. 905. World Health Organization, Geneva, Switzerland
19. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A. 2009. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti Infect. Ther. 7:157-163. http://dx.doi.org/10.1586/14787210.7.2.157
20. Pinazo MJ, Munoz J, Posada E, Lopez-Chejade P, Gallego M, Ayala E, del Cacho E, Soy D, Gascon J. 2010. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob. Agents Chemother. 54:4896-4899. http://dx.doi.org/10.1128/AAC.00537-10
21. de Pontes VM, Souza Junior AS, Cruz FM, Coelho HL, Dias AT, Coelho IC, Oliveira Mde F. 2010. [Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceara]. Rev. Soc. Bras. Med. Trop. 43:182-187. (In Portugese.) http://dx.doi.org/10.1590/S0037-86822010000200015
22. Hasslocher-Moreno AM, do Brasil PE, de Sousa AS, Xavier SS, Chambela MC, Sperandio da Silva GM. 2012. Safety of benznidazole use in the treatment of chronic Chagas' disease. J. Antimicrob. Chemother. 67: 1261-1266. http://dx.doi.org/10.1093/jac/dks027
23. Dreiseitl S, Ohno-Machado L. 2002. Logistic regression and artificial neural network classification models: a methodology review. J. Biomed. Inform. 35:352-359. http://dx.doi.org/10.1016/S1532-0464(03)00034-0
24. Chang YJ, Yeh ML, Li YC, Hsu CY, Lin CC, Hsu MS, Chiu WT. 2011. Predicting hospital-acquired infections by scoring system with simple parameters. PLoS One 6:e23137. http://dx.doi.org/10.1371/journal.pone .0023137
25. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. 1981. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30:239-245. http://dx.doi.org/10.1038/clpt.1981.154
26. Gandhi TK, Seger DL, Bates DW. 2000. Identifying drug safety issues: from research to practice. Int. J. Qual. Health Care 12:69-76. http://dx.doi.org/10.1093/intqhc/12.1.69
27. Son YM, Lee JR, Roh JY. 2011. Causality assessment of cutaneous adverse drug reactions. Ann. Dermatol. 23:432-438. http://dx.doi.org/10.5021/ad .2011.23.4.432
28. WHO Collaborating Centre for International Drug Monitoring. 2005. The WHO adverse reaction terminology. Uppsala Monitoring Centre, Uppsala, Sweden
29. Hosmer DW, Lemeshow S. 2000. Applied logistic regression, 2nd ed. Wiley & Sons, New York, NY
30. Lauritsen JM, Bruus M. 2003. A comprehensive tool for validated entry and documentation of data, 3rd ed. The EpiData Association, Odense, Denmark
31. R Development Core Team. 2013. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
32. WHO. 2010. FirstWHOreport on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. World Health Organization, Geneva, Switzerland
33. Docampo R. 1990. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem. Biol. Interact. 73:1-27. http://dx.doi.org/10.1016/0009-2797(90)90106-W
34. Stoppani AO. 1999. The chemotherapy of Chagas disease. Medicina (B Aires) 59(Suppl 2):S147-S165. (In Spanish.)
35. Castro JA, Meca MM, Bartel LC. 2006. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol. 25:471-479. http://dx.doi.org/10.1191/0960327106het653oa
36. Bartel LC, Montalto de Mecca M, de Castro CR, Bietto FM, Castro JA. 2010. Metabolization of nifurtimox and benznidazole in cellular fractions of rat mammary tissue. Hum. Exp. Toxicol. 29:813-822. http://dx.doi.org/10.1177/0960327110361756
37. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. 2004. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 113: 832-836. http://dx.doi.org/10.1016/j.jaci.2003.12.591
38. Thong BY, Tan TC. 2011. Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 71:684-700. http://dx.doi.org/10.1111/j.1365-2125.2010.03774.x
39. Yang JJ, Burchard EG, Choudhry S, Johnson CC, Ownby DR, Favro D, Chen J, Akana M, Ha C, Kwok PY, Krajenta R, Havstad SL, Joseph CL, Seibold MA, Shriver MD, Williams LK. 2008. Differences in allergic sensitization by self-reported race and genetic ancestry. J. Allergy Clin. Immunol. 122:820-827 e829. http://dx.doi.org/10.1016/j.jaci.2008.07 .044
40. Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH. 2005. Risk factors for adverse drug events: a 10-year analysis. Ann. Pharmacother. 39:1161-1168. http://dx.doi.org/10.1345/aph.1E642
41. Riedl MA, Casillas AM. 2003. Adverse drug reactions: types and treatment options. Am. Fam. Physician 68:1781-1790
42. Tornheim JA, Lozano Beltran DF, Gilman RH, Castellon M, Solano Mercado MA, Sullca W, Torrico F, Bern C. 2013. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. PLoS Negl. Trop. Dis. 7:e2407. http://dx.doi.org/10.1371/journal.pntd.0002407
43. Lobo MG, Pinheiro SM, Castro JG, Momente VG, Pranchevicius MC. 2013. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol. Toxicol. 14:5. http://dx.doi.org/10.1186/2050-6511-14-5
44. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM. 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-1413. http://dx.doi.org/10 .1016/S0140-6736(96)04128-1
45. Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H. 2011. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 127:e212-e218. http://dx.doi.org/10.1542/peds .2010-1172
46. Demoly P, Bousquet J. 2001. Epidemiology of drug allergy. Curr. Opin. Allergy Clin. Immunol. 1:305-310
47. Modayil RR, Harugeri A, Parthasarathi G, Ramesh M, Prasad R, Naik V, Giriyapura V. 2010. Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiol. Drug. Saf. 19:247-255. http://dx.doi.org/10.1002/pds.1907
48. Onder G, Petrovic M, Tangiisuran B, Meinardi MC, Markito-Notenboom WP, Somers A, Rajkumar C, Bernabei R, van der Cammen TJ. 2010. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the Geronto-Net ADR risk score. Arch. Intern. Med. 170:1142-1148
49. Carrilero B, Murcia L, Martinez-Lage L, Segovia M. 2011. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Rev. Esp. Quimioter. 24:123-126
50. Gallagher PF, O'Connor MN, O'Mahony D. 2011. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin. Pharmacol. Ther. 89:845-854. http://dx.doi.org/10.1038/clpt.2011.44.